Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-04-03 @ 3:22 PM
Study NCT ID:
NCT00473694
Status:
COMPLETED
Last Update Posted:
2019-03-19
First Post:
2007-05-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-11-28
Start Date Type:
ACTUAL
Primary Completion Date:
2006-11-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2007-01-29
Completion Date Type:
ACTUAL
First Submit Date:
2007-05-14
First Submit QC Date:
None
Study First Post Date:
2007-05-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-11-08
Results First Submit QC Date:
None
Results First Post Date:
2019-03-07
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-03-06
Last Update Post Date:
2019-03-19
Last Update Post Date Type:
ACTUAL